Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors.
Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors.
复制标题
DOI：
10.3390/cancers13143486
复制
发表时间：
2021-07-12
期刊：
影响因子：
5.2
通讯作者：
Okabe H
中科院分区：
文献类型：
--
作者：
Yamazaki H;Suzuki G;Masui K;Aibe N;Shimizu D;Kimoto T;Yamada K;Shiraishi T;Fujihara A;Okihara K;Yoshida K;Nakamura S;Okabe H
我们探索了每个极高风险因素的作用，发现简单地将极高风险(VHR)因素(T3b-4和Gleason评分9-10)的数量相加是区分VHR-2(T3b-4和Gleason评分9-10)和其他因素(VHR-1；T3b-4或Gleason评分9-10，VHR-0；T3b-4和Gleason评分9-10)的一种简单且非常高的预测力。VHR-2组的生化控制率和无远处转移生存率显著低于其他组，导致前列腺癌特异性死亡率高于VHR-1和VHR-0组。本研究旨在探讨极高风险(VHR)因子(T3b-4和Gleason评分9-10)对临床局限性高危前列腺癌预后的影响。我们回顾了1413例接受放射治疗的患者(558例接受外照射(EBRT)和855例接受近距离放射治疗(BT)±EBRT)的多机构回顾数据。我们通过简单求和VHR因素的数量-VHR-0、VHR-1和VHR-2引入了一个指数。中位随访69.6个月，VHR-2组5年无生化疾病生存率(BDFS)、前列腺癌特异性死亡率(PCSM)和无远处转移生存率(DMSF)分别为59.4%、7.65%和83.2%，VHR-1组分别为86.7%、1.50%和95.4%，VHR-0组分别为93.1%、0.12%和98.2%。VHR-2组的bDFS、PCSM和DMSF显著低于VHR-0组(风险比分别为4.55、9.607和7.904)和VHR-1组(风险比分别为1.723、2.391和1.491)。与其他组相比，VHR-2组可以被确定为超高风险组，并且可能是使用多模式强化治疗的临床试验的良好候选者。对于bDFS、PCSM和DMSF，VHR因素的简单求和是一个简单而有用的预测指标。
We explored the role of each very high-risk factor and found that simple summation of the number of very high-risk (VHR) factors (T3b–4 and Gleason score 9–10) is an easy and very high predictive power to separate VHR-2 (both T3b–4 and Gleason score 9–10) and others (VHR-1; T3b–4 or Gleason score 9–10, VHR-0; none of T3b–4 and Gleason score 9–10). The VHR-2 group showed a strikingly lower biochemical control rate and distant metastasis free survival rate than other groups, resulting in higher prostate cancer specific mortality than the VHR-1 and VHR-0 groups. This study aimed to examine the role of very high-risk (VHR) factors (T3b–4 and Gleason score 9–10) for prognosis of clinically localized high-risk prostate cancer. We reviewed multi-institutional retrospective data of 1413 patients treated with radiotherapy (558 patients treated with external beam radiotherapy (EBRT) and 855 patients treated with brachytherapy (BT) ± EBRT. We introduced an index by simple summation of the number of VHR factors—VHR-0, VHR-1, and VHR-2. With median follow-up of 69.6 months, the 5-year biochemical disease free survival rate (bDFS), prostate cancer-specific mortality (PCSM), and distant metastasis-free survival (DMSF) rates were 59.4%, 7.65%, and 83.2% for the VHR-2 group, respectively; 86.7%, 1.50%, and 95.4% for the VHR-1 group, respectively; and 93.1%, 0.12%, and 98.2% for the VHR-0 group, respectively. The VHR-2 group had significantly worse bDFS, PCSM, and DMSF than the VHR-0 (hazard ratios: 4.55, 9.607, and 7.904, respectively) and VHR-1 (hazard ratios: 1.723, 2.391, and 1.491, respectively) groups. The VHR-2 group could be identified as a super high-risk group compared with other groups, and could be a good candidate for clinical trials using multimodal intensified treatments. Simple summation of the number of VHR factors is an easy and useful predictive index for bDFS, PCSM, and DMSF.
登录
查看更多内容
对医疗统计信息的自由使用的易于使用的软件“ EZR”的调查。
影响因子：
4.8
作者：
Kanda Y
通讯作者：
Kanda Y
影响因子：
2.6
作者：
Kasahara, Takashi;Ishizaki, Fumio;Tomita, Yoshihiko
通讯作者：
Tomita, Yoshihiko
影响因子：
2
作者：
Sasaki, Naomi;Yamazaki, Hideya;Yoshida, Ken
通讯作者：
Yoshida, Ken
影响因子：
5.6
作者：
Epstein, Jonathan I.;Amin, Mahul B.;Humphrey, Peter A.
通讯作者：
Humphrey, Peter A.
影响因子：
4.8
作者：
Sundi, D.;Wang, V. M.;Pierorazio, P. M.;Han, M.;Bivalacqua, T. J.;Ball, M. W.;Antonarakis, E. S.;Partin, A. W.;Schaeffer, E. M.;Ross, A. E.
通讯作者：
Ross, A. E.